How should cardiovascular symptoms be managed in a patient with DRESS syndrome?

Management of Cardiovascular Symptoms in DRESS Syndrome

Patients with DRESS syndrome require immediate cardiac monitoring and supportive care focused on fluid/electrolyte balance, with high-dose corticosteroids (IV methylprednisolone 0.5-2 mg/kg) as the cornerstone of treatment, and ICU admission should be strongly considered given the significant morbidity associated with cardiac involvement.

Initial Assessment and Monitoring

When DRESS syndrome is suspected, perform a comprehensive cardiac workup immediately:

• Cardiac biomarkers: Troponin and brain natriuretic peptide 1
• Electrocardiogram: New abnormalities detected in up to 42% of patients with cardiac involvement 2
• Cardiac imaging: Echocardiogram to assess for myocarditis and ventricular function 3, 4
• Continuous cardiac monitoring: Telemetry for arrhythmia detection 5

Critical point: Cardiac involvement occurs in 15.2% of DRESS cases and is associated with higher ICU admission rates (67% vs 34%) 2. Dyspnea is the most frequent cardiac symptom, reported in up to 20% of patients 2.

Immediate Management Algorithm

Grade 3-4 DRESS with Systemic Symptoms

1. Admit immediately to ICU or burn unit 1
2. Discontinue offending drug permanently (antibiotics are most common culprit) 2
3. Initiate IV methylprednisolone:
   • Grade 3: 0.5-1 mg/kg 1
   • Grade 4: 1-2 mg/kg 1
   • Taper over at least 4 weeks when toxicity resolves 1

Supportive Cardiovascular Care

Fluid and hemodynamic management is critical:

• Careful attention to fluid and electrolyte balance 1
• Minimize insensible water losses 1
• For hypotension: IV fluid boluses, then vasopressors if refractory 5
• Hemodynamic monitoring in ICU setting 5

Key caveat: Eosinophilic myocarditis can progress to acute necrotizing myocarditis, cardiac thrombosis, and fibrotic stages 3. Symptoms range from asymptomatic to cardiogenic shock 3.

Steroid-Refractory Cases

If cardiovascular symptoms persist despite corticosteroids:

• IVIG (intravenous immunoglobulin) 1, 6
• Cyclosporine 1, 6
• Cyclophosphamide (severe cases) 6
• Ventricular assist devices may be needed in refractory cardiac failure 3

Ongoing Monitoring Strategy

Prolonged immunosuppression is often required in DRESS cases, particularly with cardiac involvement 1. The immune suppression may need to be extended beyond typical timelines due to the T-cell mediated toxicity mechanism 1.

Monitor for:

• Renal involvement: 100% of DRESS patients with cardiac involvement had concurrent renal involvement 2
• HHV-6 reactivation: Can occur even without drug trigger and contribute to myocarditis 7
• Late cardiac manifestations: Myocarditis may occur long after initial DRESS diagnosis 4

Multidisciplinary Consultation

Essential consultations:

• Dermatology (immediate) 1
• Cardiology for cardiac involvement management 3
• Pain/palliative care for severe DRESS manifestations 1

Evidence Strength and Clinical Context

The ASCO 2021 guidelines 1 provide the strongest framework, though they focus on immune checkpoint inhibitor-related DRESS. The principles apply universally: corticosteroids remain the cornerstone of treatment 3, 4. Recent 2026 data 2 confirms cardiac involvement is under-recognized but clinically significant, with no mortality directly attributable to cardiac involvement when properly managed, though overall mortality is higher in severe cutaneous adverse reactions.

Common pitfall: Delaying corticosteroid initiation while awaiting definitive cardiac diagnosis. Start steroids immediately when DRESS with systemic symptoms is suspected, as early treatment prevents progression to life-threatening cardiac complications 3, 4.